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Abstract 
The application of mild hypothermic conditions to cell culture is a routine industrial practice used to 
improve recombinant protein production. However, a thorough understanding of the regulation of 
dynamic cellular processes at lower temperatures is necessary to enhance bioprocess design and 
optimisation. In this study, we investigated the impact of mild hypothermia, where Chinese hamster 
ovary (CHO) cells expressing a mAb were cultured at 36.5°C and with a temperature shift to 32°C 
during late exponential/early stationary phase, on protein glycosylation. Experimental results 
showed higher cell viability with decreased metabolic rates. The specific antibody productivity 
increased by 46.2% at 32°C and was accompanied by a reduction in intracellular nucleotide sugar 
concentrations and a decreased proportion of the more processed glycan structures on the IgG 
molecules. To better understand CHO cell metabolism at 32°C, flux balance analysis (FBA) was 
carried out and constrained with exometabolite data from stationary phase of cultures with or 
without a temperature shift. Estimated fluxomes suggested reduced fluxes of carbon species 
towards nucleotide and nucleotide sugar donor synthesis, and more energy was used for product 
formation. Expression of N-glycosyltransferases that are responsible for N-glycan branching and 
elongation were significantly lower at 32°C. As a result of mild hypothermia, mAb glycosylation 
was shown to be affected by both nucleotide sugar donor availability and glycosyltransferase 
expression. The combined experimental/FBA approach generated a more fundamental view of how 
product glycosylation can be impacted by changes in culture temperature. Better feeding strategies 
can therefore be developed based on the understanding of the metabolic flux distribution. 
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Introduction 
With positive outcomes from medical treatments, biologics are one of the fastest growing drug 
groups in the pharmaceutical market, with monoclonal antibodies (mAbs) among the top five best-
selling biologics (Aggarwal 2014). In order to increase the specific productivity of recombinant 
protein (qP), optimisation of industrial bioprocesses continues to be an important focus. The use of 
biphasic cultures involving a shift in temperature or pH is an approach to increase recombinant 
protein (rProtein) production yield. For example by reducing culture temperature from 37°C to 
33°C, Nam et al achieved a nearly 8-fold increase in the specific productivity of recombinant 
secreted human placental alkaline phosphate (SEAP) in suspension Chinese hamster ovary (CHO) 
cell culture (Nam et al. 2008). A shift to mild hypothermic conditions (30°C - 34°C) has therefore 
become the very frequently employed industrial practice in rProtein production in CHO cell lines 
(Wulhfard et al. 2008). Not only does mild hypothermia affect rProtein productivity, it also slows 
down cell metabolism, reduces the rate of nutrient consumption and production of biological waste 
(Chuppa et al. 1997), causes the partial arrest of the cell population in G0/G1 phase of the cell cycle 
(Marchant et al. 2008), and stabilises transcriptional species as well as changing the efficiency of 
protein translation, folding and trafficking (Cain et al. 2013).  
With an increasing demand for mAbs, research has led to tailoring of product quantity through mild 
hypothermia; however few investigations have been made into its effects on the glycosylation of the 
recombinant products. Regardless of the type of glycoprotein, the sugars attached contribute to 
protein folding, stability, trafficking, biological activity and serum clearance. In the case of IgG, its 
Fc-domain controls the activation of downstream immune responses upon binding to Fcγ receptors, 
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where the ability of binding and the drug efficacy is influenced by the glycosylation pattern on the 
Fc-region. For instance, the absence of core-fucosylation results in the increase in Antibody-
Dependent Cell-Mediated Cytotoxicity (ADCC) activity by approximately 50-fold (Shinkawa et al. 
2003), while terminal galactosylation increases Complement-Dependent Cytotoxicity (CDC) 
activity of IgG molecules through higher binding affinity of the mAbs to the C1q complement 
molecules (Hodoniczky et al. 2005). The final glycan structure of the product is dependent on the 
expression levels and the activities of glycosyltransferases, as well as the availability of nucleotide 
sugar donors (NSDs), which are substrates of glycosyltransferases during glycan processing. NSD 
synthesis is highly influenced by the presence of key nutrients during cell culture (Murrell et al. 
2004), e.g. glucose and galactose (Figure 1); as a result changes in cell metabolism during mild 
hypothermia can impact the glycosylation of the mAb. To ensure consistency in mAb quality, a 
thorough understanding of the relationships among cell metabolism, mAb synthesis and Fc-
glycosylation is necessary.   
In this study, we examined the impact of mild hypothermia on an IgG-expressing CHO cell line and 
compared culture performance at different temperatures with respect to cell growth, metabolic 
profile (nutrients, biological wastes, amino acids and NSDs), mAb synthesis including heavy and 
light chain mRNA and assembly intermediates, as well as mAb glycan profiles and 
glycosyltransferase expression levels. We then performed flux balance analyses on data sets from 
both temperatures in order to generate a better understanding of the intracellular metabolic networks 
through calculating differences in metabolic flux changes upon the induction of mild hypothermia. 
Material and Methods 
Cell line and maintenance 
An IgG-producing Chinese hamster ovary CHO-T cell line (MedImmune, Cambridge, UK) was 
revived and cultured in CD-CHO medium (Life Technologies, Paisley, U.K.) where 50 µM 
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methionine sulfoximine (MSX) was supplemented during the first and second passages only, and 
was shaken at 140 rpm in humidified 36.5°C incubator with 5% CO2 supply. Cells were subcultured 
in fresh medium every three days at a seeding density of 3 x 105 viable cells/mL. Cell concentration 
and cell viability were measured by ViCell (Beckman Coulter, CA, U.S.A.). Cells were 
transferred into the bioreactor system after 3 cell passages. 
Cell system and Operation 
Shake flasks were used in the culture of CHO cells prior to transfer into 1.5 L continuous- stirred 
tank DASGIP bioreactors (DASGIP Technology, Juelich, Germany) where each condition was 
examined in triplicate bioreactors. Each bioreactor contained an initial culture volume of 0.9 L with 
a starting viable cell density of 8 x 105 cells/mL. Within the 14-day cell culture period, the cultures 
were maintained at pH 6.9±0.1 at 36.5°C, or with a temperature shift to 32°C on day 6 post 
inoculation, with a stirring speed at 150 rpm and CO2 air concentration at 5% v/v. On days 2, 4, 6, 
8, 10 and 12 of the culture period, the cultures were supplemented with 10% by volume CD 
EfficientFeedTM C AGTTM Nutrient supplement (Life Technologies, Paisley, U.K.) and 5 mL 
additions of 15% antifoam C (Sigma-Aldrich, Dorset, U.K.) were added when excessive foaming 
occurred. 
Analytical assays 
To determine the amount of intracellular metabolite, heavy and light chain mRNA and polypeptides 
that were produced throughout the experiments, 5 x106 cells were collected for DNA/RNA 
quantification and 2 x106 cells each for HC/LC mRNA, polypeptide and NSD analyses. Cells were 
centrifuged at 200 rpm for 5 minutes in an Eppendorf microfuge, cell pellets were washed twice 
with PBS.  Clarified supernatants were used to determine extracellular nutrient and secreted mAb 
concentrations. Both pellets and supernatant samples were stored at -80°C.  
(a) Nutrients, metabolites and secreted mAb concentrations 
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Extracellular concentrations of glucose, lactate and ammonia in supernatant samples were 
determined using the YSI Bioprofiler 800 (NOVA Biomedical, MA, U.S.A.). Extracellular amino 
acid quantification was performed with a Waters Acquity ultra-performance liquid chromatography 
(UPLC, Waters, Hertfordshire, U.K.) using the AccQ-tag kit according to the manufacturer’s 
instructions. Secreted mAb titre was determined using a Protein-A affinity chromatography method. 
(b) DNA and RNA extraction and cDNA preparation 
The total DNA and RNA of each sample was extracted from cell pellets using the All prep 
DNA/RNA mini purification kit (Qiagen, Manchester, U.K.) as described in the manufacturer’s 
instructions. 300 ng of extracted RNA from each sample was reversed transcribed into cDNA using 
1 µL of the RT Primer Mix of the QuantiTect Reverse Transcription Kit (Qiagen, Manchester, 
U.K.). 
(c) mAb heavy and light chain, glycosyltransferase mRNA measurement 
mRNA expression levels of mAb heavy (HC HuG1) and light chains (LC HuKappa) in each sample 
were quantified by quantitative real-time polymerase chain reaction (qRT-PCR). Each sample was 
analysed in triplicate PCR reactions. A total of 10 µL of reaction volume was used per sample in a 
96 well-plate, with 5 µL of 2x SYBR Green Supermix (Sigma-Aldrich, Dorset, U.K.), 0.64 µL of 
cDNA and 500 nM of each primer. Non-template controls were carried out for each PCR reaction. 
PCR reactions were initiated with 3 min at 95 °C for SYBR Green activation; followed by 40 cycles 
of 95°C for 30 s, 60°C for 75 s and 72°C for 30 s. The product integrity was verified by the DNA 
melting curve from 65°C to 95°C (read every 0.3°C). Results were compared to the Ct-number of a 
house-keeping β-actin gene for relative analysis. Primer sequences are available on request. 
(d) Determination of heavy and light chain mRNA half-lives 
To estimate the stability of heavy and light chain mRNA molecules, duplicate shake flask 
experiments were performed at both 36.5°C and 32°C. At late exponential phase (day 6) of each 
culture, 65 µM of the transcription inhibitor DRB (5,6 dichloro-1 β-D-ribofuranosyl 
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benzinmidazole, Sigma-Aldrich, Dorset, U.K.) dissolved in 100% ethanol (VWR, Lutterworth, 
U.K.) was added to block cell transcription. The same volume of ethanol was added to the control 
cultures at both temperatures to compensate for the effect of ethanol on the cells. 5 x 106 cells/mL 
were collected from each culture at 0, 3, 6, 9, 12 hours after the inhibitor/ethanol additions. 
Transcribed cDNA from each sample were quantified by qRT-PCR. Results were normalized to a 
standard curve generated with known amounts of the HC/LC plasmids and their respective Ct-
values. mRNA levels were determined from their respective standard curves and decay rates were 
calculated. 
(e) Intracellular mAb polypeptides and assembly intermediate analysis 
Cell pellets with 2 x 106 viable cells were washed with PBS at 4°C to remove any supernatant 
residue. The PBS was aspirated and cell pellets were resuspended in 125 µL of CellLyticTM M 
solution (Sigma-Aldrich, Dorset, U.K.) supplemented with 1% (v/v) protease inhibitor cocktail 
(Sigma-Aldrich, Dorset, U.K.). Mixtures were incubated at room temperature on an orbital shaker 
for 15 min. The lysates were spun at 18,000 x g for 15 min. The protein-containing supernatant was 
stored at -80°C prior to Western blot analysis. 4 µL of 4x NuPAGE sample buffer was added to 12 
µL of each sample and 100, 10, 1 and 0.1 µg of purified IgG controls (provided by MedImmune, 
Granta Park, Cambridge, U.K.). Each sample was run on 12% Precast Protein gel (Thermo 
Scientific, Horsham, U.K.) in Tris-HEPES running buffer at 120 V for 1 h. The polyacrylamide gel 
was washed twice with dH2O before being transferred in a semi-dry transfer system (Bio-Rad, 
Hertfordshire, U.K.) onto a methanol-activated PVDF transfer membrane (Millipore, Watford, 
U.K.) at 0.3 A for 50 min. After successful transfer, 1:1000 horseradish peroxidase (HRP)-
conjugated goat anti-human IgG Fc primary antibody (Jackson Immunoresearch, PA, U.S.A.) was 
used as the primary antibody and visualisation proceeded with the WesternBreeze 
Chemiluminescent Anti-Goat-Kit (Life Technologies, Paisley, U.K.) according to the 
manufacturer’s instructions and using a 10 min exposure time (FujiFilm, Bedford, U.K.). The 
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intensity of each band was quantified using MYImageAnalysis Software Manual (Thermo 
Scientific, Horsham, U.K.) and concentrations were determined through comparison to the IgG 
protein standard.    
(f) Analysis of galactosyltransferase III (GalTIII) protein expression 
2 x 106 viable cell pellets were rinsed with 4°C PBS prior to cell lysis in 200 µL of M-PER 
Mammalian protein extraction reagent (Thermo Scientific, Horsham, U.K.) supplemented with 1% 
(v/v) protease inhibitor cocktail (Sigma-Aldrich, Dorset, U.K.). Sampled were gently shaken for 10 
min before they were sonicated at 3 burst of 5 seconds on ice, with 25 seconds intervals and an 
amplitude power of 20. Cell debris was removed by centrifugation at 14,000 x g for 15 min. 
Membrane protein-containing supernatant was stored at -80°C prior to Western blot analysis as 
described in (e), with an exception of 10 min 100°C sample incubation before gel electrophoresis. 
β-1,4-Gal-T3 Antibody (N20) (Santa Cruz Biotechnology, Texas, USA) was used as primary 
antibody for western blotting and protein concentration in each sample was compared to known 
concentrations of β-1,4-Gal-T3 (N20) blocking peptide (Santa Cruz Biotechnology, Texas, USA). 
(g) Extraction of intracellular NSD and analysis 
Intracellular nucleotide sugars were extracted by an acetonitrile extraction method (Dietmair et al. 
2010; Viant et al. 2005). In brief, 400 µL of ice cold 50% v/v aqueous acetonitrile was added to a 
cell pellet containing 2 x 106 cells. The mixture was incubated on ice for 10 min before 
centrifugation at 18,000 x g for 5 min at 0°C. Supernatant was dried thoroughly using a SpeedVac 
(Savant Inc. Laboratory, MI, U.S.A.). Dried samples were resuspended in 150 µL of deionised 
water and were filtered by 0.2-µm syringe filter units (Fisher Scientific, Loughborough, U.K.) 
before HPAEC analysis. The NSD analytic method was based on del Val et al. (2013), using a 
CarboPac PA-1 column with a PA-1 guard column (Dionex, CA, USA). Elution of samples was 
done using a gradient of E1 (3 mM NaOH) and E2 (1.5 mM sodium acetate in 3 mM NaOH) 
buffers as mobile phases. Detection of all species was carried out at two absorbance wavelengths: 
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271.6 nm for all cysteine-bearing species and 262.1 nm for the rest of all other compounds. This 
method was capable to resolve 10 nucleotides -  ATP, CTP, GTP, UTP, AMP, ADP, CMP, GMP, 
UMP and UDP, as well as 9 nucleotide sugar compounds o CMP-Neu5Ac, UDP-GalNAc, UDP-
GlcNAc, UDP-Gal, UDP-Glc, GDP-Fuc, GDP-Man, GDP-Glc and UDP-GlcA.  
(h) mAb glycan analysis 
Purified mAb samples with concentration range of 1.25 - 7.5 mg/mL were prepared for glycan 
analysis using the ProfilerPro Glycan Profiling Kit (PerkinElmer, MA, U.S.A.). 8 µL of samples 
were firstly denatured in the Denaturing Plate containing 3 µL of denaturing solution for 10 min at 
70°C. 11 µL of denatured materials were next transferred to Peptide-N-Glycosidase F (PNGase F) 
Plate and was incubated at 37°C for 1 h to separate glycan from the protein. 8 µL of the digested 
samples were transferred to the Labelling Plate and was incubated at 55°C for 2 h for glycan 
labelling. Dried samples were reconstituted in 100 µL of molecular grade water and glycan analysis 
was performed by the LabChip GXII instrument (PerkinElmer, MA, U.S.A.).  
Flux balance analysis (FBA) 
The R workspace (R Development Core Team 2010) and the Sybil package (Gelius-Dietrich et al. 
2013) were used to perform the FBA. The metabolic network was constructed by Kyriakopoulos 
and Kontoravdi (2014) based on the network proposed by Carinhas et al. (2013). The biomass 
composition used was that proposed by Selvarasu et al. (2012) for CHO cells, but excluding Cys. 
The final model consisted of 120 metabolites, 97 intracellular reactions and 57 transport equations, 
as shown in the Supplementary Table 2. The model was optimised by assuming maximum biomass 
and IgG accumulation during exponential phase, and maximum IgG accumulation at stationary 
phase. FBA was conducted based on the experimentally measured concentrations of extracellular 
amino acids, glucose, lactate, ammonia and viable cell density and IgG titres. The upper and lower 
limits were set within 1 standard deviation while the remaining extracellular fluxes were set at 
±20% (Carinhas et al. 2013). Choline was included in the network to account for lipid synthesis. In 
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order to examine the glucose fluxes to nucleotide and NSD production for glycosylation, GlcNAc, 
GalNAc, Mann, Fuc, Gal and Neu5Gc were added in the biomass equation. The amount of each 
NSD necessary for host cell protein glycosylation , was estimated based on the results from the MS 
glycan study in Stanley (2010), as well as the occurring frequency of N- and O-linked glycans 
based on Apweiler et al. (1999). These data were then used to calculate the respective 
stoichiometric coefficients (mmol per gram of dry cell weight, mmol/gDCW) that were 
incorporated in the biomass equation and used in the FBA analysis.  
Results  
CHO cell culture behaviour and mAb production profile during mild hypothermia 
Two sets of experiments were carried out to investigate the impact of mild hypothermia: 14-day 
CHO cell fed-batch culture at 36.5°C or with a temperature shift from 36.5°C to 32°C on day 6 at 
late exponential phase. Figures 2A and B show the growth profiles of CHO cell cultures and their 
specific mAb productivities at both temperatures. When compared to culture at 36.5°C, cells that 
were temperature-shifted to 32°C maintained a high viability of 98.2% on harvest day with only a 
10.0% reduction in their integral viable cell concentration (IVCC). Accompanied with increased 
cell viability, a 46.2% rise in the specific mAb productivity was observed. To better elucidate the 
increase in qmAb at lower temperature, intracellular species produced in the mAb synthesis process 
were experimentally quantified. Results show that only the heavy chain mRNA expression level 
was higher at 32°C (Figures 3A and B), while at a translational level the overall concentrations of 
H2 and H2L mAb assembly intermediates increased upon temperature shift (Figures 3C and D). In 
both mRNA and polypeptide concentrations, our results suggest the heavy chain to be the rate-
determining species for mAb synthesis, with the increase in HC mRNA transcripts at 32°C being 
advantageous for overall mAb production (Figure 3E). This is in good agreement with findings of 
O'Callaghan et al. (2010) where they concluded that qmAb was controlled mostly by the rate of HC 
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translation. In addition, a lower culture temperature was shown to stabilise both HC and LC mRNA, 
with 14% and 22% reductions in HC and LC mRNA decay rates (Table 1), respectively. 
The impact of mild hypothermia on nucleotide sugar donor synthesis and mAb glycosylation  
To ensure product quality, the final secreted mAb Fc-glycan profile was analysed on days 8, 10, 12 
and 14 for both temperatures. With respect to time, the terminal glycan structures observed in 
harvest products were comparable to those on days 8, 10 and 12. With mild hypothermia, alongside 
with the increased in mAb protein titre, we observed a significant increase in the proportion of IgG 
molecules with underprocessed glycan structures, approximately 3% and 17% increase in G0 and 
G0F, respectively and also 15% and 3% reduction in the fraction of the more processed glycoforms 
namely G1F and G2F, respectively on day 12 (Figure 4A).  
Murrell et al. (2004) demonstrated the complexity of the intracellular NSD synthetic pathway, 
where the type of sugar source (glucose, galactose, mannose etc.) and their uptake rate affected the 
production of nucleotide sugars, the building components for protein glycosylation. The availability 
of glutamine in the system was also critical for nucleotide synthesis. Quantification of the 
intracellular NSD concentrations was therefore a useful approach to understand the relationship 
between CHO cell metabolism and product glycosylation. UDP-Glc is essential in the initiation of 
N-linked glycosylation due to its role in dolichol-linked precursor oligosaccharide 
(GlcNAc2Man9Glc3) generation in the ER lumen. The intracellular concentration of UDP-Glc 
remained similar at exponential phases. However, in part due to reduced consumption of glucose 
during mild hypothermia, the amounts of UDP-Glc, UDP-Gal and UDP-GlcNAc (essential for 
glycan branching and elongation) within the cells decreased upon temperature shift (Figures 4 B-D).  
Impact of mild hypothermia on expression of genes related to N-glycosylation  
From the glycan analysis we observed an increase in the underprocessed glycan structures in the 
secreted mAb produced at 32°C. In addition to cell metabolic adjustments induced by mild 
hypothermia where it affected the availability of key NSDs for mature glycoform formation, 
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expression of proteins that are involved in N-linked glycosylation could be temperature sensitive. 
Thus, we investigated the mRNA expression levels of 6 NSD glycosyltransferase enzymes, namely 
2 N-acetylglucosaminyltransferases (GnTI and GnTII) which are involved in glycan branching, 3 
galactosyltransferases (β-GalTI, II and III) and fucosyltransferase (FucT) that adds GDP-Fuc onto 
the N-glycan core in IgG. In addition, we examined the mRNA expression levels of 2 transporters:  
UDP-Gal and UDP-GlcNAc transporters, responsible for exchanges of their respective NSDs 
between the Golgi apparatus and the cell cytosol. Figure 5A describes the transcript expression 
profiles at both temperatures. The glycosyltransferases GnTII, GalTI, GalTIII, and FucT showed 
significantly lower mRNA expression levels at 32°C. Overall, GnTI, GalTII and the two 
transporters examined did not show significant variation in their expression levels, apart from a 
drop in mRNA level of UDP-GlcNAc T at day 14 of the mild hypothermic cultures. The 
downregulation of GalTIII gene expression observed at 32°C was further supported by the 
reduction in β-1,4-GalT-III protein expression in cells cultured in mild hypothermic condition 
(Figure 5B).   
The impact of mild hypothermia on CHO cell metabolism through flux balance analysis and 
experimental studies  
Prompted by the reduction in NSD availability observed at 32°C, flux balance analysis (FBA) was 
applied to understand how lower culture temperature impacted on CHO cell metabolism. Prior to 
performing the FBA, the consumption and production rates of each exometabolite measured were 
calculated with the rate calculation code of (Kyriakopoulos 2014). Table 2 shows the calculated 
production and consumption rates of each exometabolite during the two phases at both 
temperatures. The overall amino acid and glucose exchanges from the extracellular environment 
were higher at exponential than at stationary phase. By comparing the two temperatures at 
stationary phase, we can see there was a reduction in the consumption rates of metabolites at 32°C, 
together with a shift from lactate production to consumption which correlated well with 
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experimental data. The rate of IgG production was also higher at 32°C. The FBA was then 
constrained with the rates of exometabolites, maximum qmab and growth rate (µ) during exponential 
(days 3-6) growth, but maximum qmab and exometabolite uptake/production rates only at late 
exponential/stationary phase (days 7-10). Results from the FBA (Figure 6) showed that during 
exponential growth the flux of glucose entering the TCA cycle through glycolysis was less than that 
during stationary phase, when there was increased storage of carbon as glycogen and higher fluxes 
out from the TCA into biomass, IgG, amino acid and energy generations to sustain cell growth at 
exponential growth. At 36.5°C, the flux of glucose from glycolysis to the TCA during stationary 
phase increased and the TCA cycle was more efficient, with reduced flow of species toward 
biomass/IgG production. However, when mild hypothermia was induced, lactate became the main 
fuel for the TCA cycle, with no carbon loss to glycogen production. This metabolic shift from 
glucose to lactate was supported by the dramatic drop of extracellular lactate concentration 
observed experimentally (Figure 7B).  
While most of the product generated from glycolysis was consumed within the TCA cycle at 
36.5°C, at 32°C less energy was spent on the TCA cycle, the consumption of glutamate was higher, 
where glutamate fluxes towards glutamine and aspartate syntheses increased with mild 
hypothermia, which contributed to the increase in IgG production. Moreover, the conversion rate 
from glucose-6-phosphate into ribulose-5phosphate (R5P) and NADPH was 21 times lower at 
32°C. This contributed to reduced synthetic rates of nucleotide, NSD and lipids. Supplementary 
Table 3 illustrates the lower fluxes of carbon and energy sources entering into all the three synthetic 
pathways at 32°C, accompanied by increase production of glutamine and a high exchange rate of 
glutamine from the cell cytosol to the extracellular environment. In addition, the synthesis of 
hexosamines (GlcNAc, GalNAc) requires glutamine and a reduced flux of glutamine into 
nucleotide/NSD synthesis was suggested by the FBA, which caused the drop of UDP-GlcNAc 
concentration that was measured experimentally. 
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Through experiments, CHO cells were shown to be metabolically less active when the temperature 
was lowered to 32°C at late exponential phase. Glucose was the main carbon source in the cultures 
and at 32°C we observed a reduction in glucose consumption, reflected by the higher extracellular 
glucose concentration in Figure 7A. This coincided with the estimation from the FBA where less 
glucose entered into glycolysis. On the other hand, cells achieved an increase in extracellular 
ammonia level upon temperature shift (days 6-10) but it levelled out with the concentration 
obtained at 36.5°C on day 10, when most NH4 was consumed to generate glutamine (Figure 7C).  
 
Discussion 
The adaptations that CHO cells undergo in response to mild hypothermia have led to significant 
changes in the productivity and the glycoform composition of the mAb. The prolonged cell viability 
that we observed in this study could be explained by the work of Marchant et al. (2008) which 
demonstrated that cells experienced a partial cell cycle arrest upon mild hypothermia. Instead of 
dividing cells for high cell density, more energy was generated within the TCA to sustain other 
intracellular activities, such as mAb protein synthesis and trafficking. 
As expected, at exponential growth, higher proportions of energy and amino acids were consumed 
for biomass formation, while reduced consumption towards cell growth was observed at stationary 
phase. During mild hypothermia, there was an increased net flux of amino acids into IgG protein 
synthesis, which was illustrated by a 46.2% rise in the rate of mAb production. As a result of slower 
cell metabolism, more energy is likely to have been channelled towards protein production, which 
could have consequently led to reduced inputs towards protein glycosylation.  
In addition, the reduced consumption of glucose that was experimentally observed was mirrored by 
a lowered influx of extracellular glucose into glycolysis shown in our FBA, where a metabolic shift 
to lactate consumption was triggered by the reduced production of NADH. This was to maintain the 
TCA cycle efficiency during stationary phase. However, the synthesis of nucleotides and nucleotide 
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sugars relied on the availability of glucose and glycolysis species namely glucose-6-phosphate and 
fructose-6-phosphate, together with R5P generated from the pentose-phosphate pathway, which is 
fuelled from glycolysis. The reduced metabolic rates in these pathways resulted in lower synthetic 
rates of the glycosylation substrates. Since the transcript expression of GnTII, GalTs and FucT were 
shown to be lower under mild hypothermia, accompanied by reduced GalT protein expression at 
32°C, decrease in NSD synthesis, UDP-GlcNAc and UDP-Gal in particular, together with lower 
glycosyltransferase expression levels restrict the formation of bi-antennary and more complicated 
glycan profiles which require terminal galactosylation.  
In addition, lipid synthesis relies on availability of G6P, AcCoA and various amino acids. The 
decrease in lipid synthesis calculated by the FBA could affect the generation of cell membranes and 
transport vesicles, which are important in the embedment for nucleotide-sugar transporters into the 
lipid bilayers.  
By combining experimental data with the FBA approach, we managed to draw a relationship among 
the increase in mAb synthesis, the deceleration in cell metabolism and reduced maturation of mAb 
glycan structures during mild hypothermia. Figure 8 provides an overview of how mAb 
glycosylation can be influenced by lowering culture temperature. The low metabolic state of cells 
reduced NSD synthesis as well as glycosyltransferase expression, GalT in particular, which directly 
impacted on the process of protein glycosylation. Under mild hypothermic condition, a higher 
proportion of energy and amino acid consumptions were used for product formation than NSD 
synthesis. By exploring this relationship, it may be possible to predict changes in glycan structure 
based on the effects of different bioprocess conditions on cell metabolism, as well as developing 
improved feeding strategies to target specific glycan patterns.  
Concluding remarks 
This study explored the impact of mild hypothermia on mAb N-glycosylation, by examining 
changes in cell metabolism and IgG synthesis experimentally and computationally through flux 
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balance analysis. We observed a slow-down in cell metabolism but an increase in recombinant IgG 
production when mild hypothermia was induced at stationary phase. The product quality, however, 
was influenced by culture temperature, with a higher fraction of the under-processed glycan 
structures found in the secreted IgG produced at 32°C. The relationship among a reduced cell 
metabolic rate, an increased IgG titre and the variation in product glycosylation was better 
established through the use of the FBA.  Estimated fluxomes revealed an overall lower cell 
metabolism at 32°C during stationary phase, together with decreased fluxes of carbon, energy and 
glutamine into nucleotide and NSD synthesis. More energy and metabolites were also estimated to 
contribute to a higher mAb productivity (Yoon et al. 2006), which further restricted resources that 
were necessary for mAb glycosylation. Furthermore, expression levels of key enzymes for N-linked 
glycan branching and elongation was downregulated, this in part contributed to the generation of 
pre-matured glycan structures in the secreted product. Our study allowed better clarification on the 
behaviours of CHO cells in mild hypothermia and demonstrated its impact on mAb Fc-
glycosylation, which will be beneficial for future design of experiment.  
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Table captions 
Table 1. Overview of heavy and light chain mRNA stability at 36.5°C and with temperature-shifted 
to 32°C on day 6.  
Table 2. Average specific metabolic production and consumption rates for 36.5°C and with 
temperature-shifted to 32°C on day 6. Average rates were calculated from 6 sets and 3 sets of 
experimental data that was carried out at 36.5°C and with temperature shift, respectively. All 
species are shown in femtolmol/cell/day except µ which has units of 1/day. Exponential phase: days 
3-6; stationary phase: days7-10. Negative value indicates consumption. TS: Temperature shift. 
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Figure legends 
Figure 1. NSD biosynthetic pathway in mammalian cells. Raw materials that are required for NSD 
metabolism are sugar residues: glucose (Glc), galactose (Gal), glucosamine (GlcN), fucose (Fuc) 
and mannose (Man), as well as nucleotide-precursors. NSD products are transported in the ER or 
the Golgi for protein glycosylation. Figure modified from Murrell MP et al. 2004) [9]. 
Figure 2. Cell growth and specific productivity (qmAb) of secreted IgG at 36.5°C and with a 
temperature shift to 32°C. Viable cell concentration and cell viability profiles were measured along 
the period of cell culture (A), together with the qmAb (B) which was calculated based on terminal 
secreted product, and accumulated mAb concentration profile (C) of both temperatures. Results 
were average measurements from 6 experimental data sets at 36.5°C (n=6) and 3 data sets at 32°C 
(n=3). The error bars represent the standard deviation of the six- and triplicate samples in two cases. 
TS: Temperature shift. 
Figure 3. Concentration profiles of heavy (A) and light chain (B) mRNA and H2 (C), H2L (D) 
intracellular assembly intermediates of IgG molecules at 36.5°C and 32°C TS. The overlay profiles 
of HC mRNA copy number, accumulated mAb and H2 concentrations (E) suggested heavy chain to 
be rate determining species in mild hypothermic condition. Results were average measurements 
from 6 experimental data sets at 36.5°C (n=6) and 3 data sets at 32°C TS (n=3). The error bars 
represent the standard deviation of the six- and triplicate samples in two cases. TS: Temperature 
shift. 
Figure 4. Glycan and NSD profile of the secreted IgG. Fractions of 6 glycan structures (A): Man5, 
G0, G0F, G1F, G2 and G2F on the secreted IgG products were determined, together with 
concentrations of UDP-Glc (B), UDP-GlcNAc (C) and UDP-Gal (D) that were experimentally 
measured. Results were average measurements from 6 experimental data sets at 36.5°C (n=6) and 3 
data sets at 32°C TS (n=3). The error bars represent the standard deviation of the six- and triplicate 
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samples in two cases. Statistical significance was calculated and was represented by: p≤0.05(*), 
p≤0.01(**) and p≤0.001(***). TS: Temperature shift. 
Figure 5. Expression profile of protein N-linked glycosylation enzymes (A) and relative difference 
in galactosyltransferase III (GalTIII) protein expression (B). Results were average measurements 
from 6 experimental data sets at 36.5°C (n=6) and 3 data sets at 32°C TS (n=3). The error bars 
represent the standard deviation of the six- and triplicate samples in two cases. Statistical 
significance was calculated and was represented by: p≤0.05(*), p≤0.01(**) and p≤0.001(***).TS: 
Temperature shift. 
Figure 6. Central carbon metabolism of CHO cells at exponential growth (days 3-6), stationary 
phase (days 7-10) at 36.5°C and stationary phase coupled with mild hypothermia. Thickness of an 
arrow indicates the relative flow of the carbon source within the system. This figure is simplified to 
include carbon lost to glycerol, glycogen and lactate production, together nucleotide, NSD, lipid 
and key amino acid synthesis.  
Figure 7. Overview of extracellular metabolite concentrations. Concentration profiles of 
extracellular glucose (A), lactate (B) and ammonia (C) when CHO cells were culture at 36.5°C or 
under mild hypothermia at 32°C introduced on day 6. Results were average measurements from 6 
experimental data sets at 36.5°C (n=6) and 3 data sets at 32°C (n=3). The error bars represent the 
standard deviation of the six- and triplicate samples in two cases. TS: Temperature shift. 
Figure 8. An overview of the impact of mild hypothermia on mAb glycosylation. 
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Figure 1. NSD biosynthetic pathway in mammalian cells. Raw materials that are required for NSD 
metabolism are sugar residues: glucose (Glc), galactose (Gal), glucosamine (GlcN), fucose (Fuc) and 
mannose (Man), as well as nucleotide-precursors. NSD products are transported in the ER or the Golgi for 
protein glycosylation. Figure modified from Murrell MP et al. 2004) [9].  
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Figure 2. Cell growth and specific productivity (qmAb) of secreted IgG at 36.5°C and with a temperature 
shift to 32°C. Viable cell concentration and cell viability profiles were measured along the period of cell 
culture (A), together with the qmAb (B) which was calculated based on terminal secreted product, and 
accumulated mAb concentration profile (C) of both temperatures. Results were average measurements from 
6 experimental data sets at 36.5°C (n=6) and 3 data sets at 32°C (n=3). The error bars represent the 
standard deviation of the six- and triplicate samples in two cases. TS: Temperature shift.  
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Figure 3. Concentration profiles of heavy (A) and light chain (B) mRNA and H2 (C), H2L (D) intracellular 
assembly intermediates of IgG molecules at 36.5°C and 32°C TS. The overlay profiles of HC mRNA copy 
number, accumulated mAb and H2 concentrations (E) suggested heavy chain to be rate determining species 
in mild hypothermic condition. Results were average measurements from 6 experimental data sets at 
36.5°C (n=6) and 3 data sets at 32°C TS (n=3). The error bars represent the standard deviation of the six- 
and triplicate samples in two cases. TS: Temperature shift.  
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Figure 4. Glycan and NSD profile of the secreted IgG. Fractions of 6 glycan structures (A): Man5, G0, G0F, 
G1F, G2 and G2F on the secreted IgG products were determined, together with concentrations of UDP-Glc 
(B), UDP-GlcNAc (C) and UDP-Gal (D) that were experimentally measured. Results were average 
measurements from 6 experimental data sets at 36.5°C (n=6) and 3 data sets at 32°C TS (n=3). The error 
bars represent the standard deviation of the six- and triplicate samples in two cases. Statistical significance 
was calculated and was represented by: p≤0.05(*), p≤0.01(**) and p≤0.001(***). TS: Temperature shift. 
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Figure 5. Expression profile of protein N-linked glycosylation enzymes (A) and relative difference in 
galactosyltransferase III (GalTIII) protein expression (B). Results were average measurements from 6 
experimental data sets at 36.5°C (n=6) and 3 data sets at 32°C TS (n=3). The error bars represent the 
standard deviation of the six- and tri-plicate samples in two cases. Statistical significance was calculated and 
was represented by: p≤0.05(*), p≤0.01(**) and p≤0.001(***).TS: Temperature shift.  
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Figure 6. Central carbon metabolism of CHO cells at exponential growth (days 3-6), stationary phase (days 
7-10) at 36.5°C and stationary phase coupled with mild hypothermia. Thickness of an arrow indicates the 
relative flow of the carbon source within the system. This figure is simplified to include carbon lost to 
glycerol, glycogen and lactate production, together nucleotide, NSD, lipid and key amino acid synthesis.  
209x148mm (300 x 300 DPI)  
 
 
Page 27 of 38
John Wiley & Sons
Biotechnology & Bioengineering
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Figure 7. Overview of extracellular metabolite concentrations. Concentration profiles of extracellular glucose 
(A), lactate (B) and ammonia (C) when CHO cells were culture at 36.5°C or under mild hypothermia at 32°C 
introduced on day 6. Results were average measurements from 6 experimental data sets at 36.5°C (n=6) 
and 3 data sets at 32°C (n=3). The error bars represent the standard deviation of the six- and triplicate 
samples in two cases. TS: T mperature shift.  
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Figure 8. An overview of the impact of mild hypothermia on mAb glycosylation.  
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Table 1. Overview of heavy and light chain mRNA stability at 36.5°C and with temperature-shifted to 32°C 
on day 6.  
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Table 2. Average specific metabolic production and consumption rates for 36.5°C and with temperature-
shifted to 32°C on day 6. Average rates were calculated from 6 sets and 3 sets of experimental data that 
was carried out at 36.5°C and with temperature shift, respectively. All species are shown in 
femtolmol/cell/day except µ which has units of 1/day. Exponential phase: days 3-6; stationary phase: 
days7-10. Negative value indicates consumption. TS: Temperature shift.  
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Supplementary Table 1. Forward and reverse primer pairs used in qRT-PCR experiments.  
 
*Primer sequence for the heavy and light chain can be provided upon request. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Branching: N-acetylglucosaminyl Transferases (GnT) 
GnT I  5’-CTGGGTGTCATGGATGACCT-3’ 
5’-CTAATTCCAGCTAGGATC-3’ 
GnT II  5’-GATGATTATAACTGGGACTGG-3’ 
5’-TGACTCAATTTGGGCACTCTG-3’ 
Galactosylation: Galactosyltransferases (β-Gal T) 
β-Gal T I AF318896 5’-GACCTGGAGCTTTTGGCAAA-3’ 
5’-GGGATAATGATGGCCACCTTG-3’ 
β-Gal T II AY117536 5’-CCTTCTCTGCCTGCTGCACT-3’ 
5’-CTGGGCTTCGGATACTGAAGC-3’ 
β-Gal T III AY117537 5’-AACTGCCATAATTGTGCCCC-3’ 
5’-TGCCATATGCAAGCTGCTG-3’ 
Fucosylation 
Fucosyltransferase  5’-TATGGCACCCAGCGAACACTC-3’ 
5’-TTCACCTGACCAGTGTCCAG-3’ 
Nucleotide Sugar Transporters 
UDP-Gal Transporter AF299335 5’-ACACACTCAAGCTCGCGGT-3’ 
5’-TGTCACCTGGAAAGTGGCAG-3’ 
UDP-GlcNAc Transporter  5’-CAGGAGTTGCTTTTGTACAG-3’ 
5’-GCTGTGAGAACTGCCATGAG-3’ 
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Supplementary Table 2. FBA reactions of CHO cells included in the model. 
 
# Reaction Reversibility 
 Glycolysis  
1 [c] : Glc + ATP --> G6P + ADP Irreversible 
2 [c] : G6P <==> F6P Reversible 
3 [c] : F6P + ATP --> DHAP + GAP + ADP Irreversible 
4 [c] : DHAP <==> GAP Reversible 
5 [c] : GAP + NAD + ADP <==> 3PG + NADH + ATP Reversible 
6 [c] : 3PG + ADP --> Pyr + ATP Irreversible 
 TCA cycle  
7 [c] : Pyr + NAD + CoASH --> AcCoA + CO2 + NADH Irreversible 
8 [c] : AcCoA + Oxal --> Cit + CoASH Irreversible 
9 [c] : Cit + NADP --> αKG + CO2 + NADPH Irreversible 
10 [c] : αKG + CoASH + NAD --> SucCoA + CO2 + NADH Irreversible 
11 [c] : SucCoA + GDP <==> Succ + GTP + CoASH Reversible 
12 [c] : Succ + FAD <==>  Fum + FADH2 Reversible 
13 [c] : Fum <==>  Mal Reversible 
14 [c] : Mal + NAD <==>  Oxal + NADH Reversible 
 Pyruvate fates  
15 [c] : Pyr + NADH <==>  Lac + NAD Reversible 
16 [c] : Pyr + Glu <==>  Ala + αKG Reversible 
 Pentose Phosphate Pathway  
17 [c] : (3) G6P + (6) NADP --> (3) CO2 + (3) R5P + (6) NADPH Irreversible 
 Anaplerotic Reaction  
18 [c] : Mal + NADP <==>  Pyr + HCO3 + NADPH Reversible 
 Amino Acid Metabolism  
19 [c] : Glu + NADP <==>  αKG + NH4 + NADPH Reversible 
20 [c] : Oxal + Glu <==>  Asp + αKG Reversible 
21 [c] : Gln + ADP <==>  Glu + ATP + NH4 Reversible 
22 [c] : Thr + NAD + CoASH --> Gly + NADH + AcCoA Irreversible 
23 [c] : Ser + THF + NADP <==>  Gly + NADPH + N10FTHF Reversible 
24 [c] : N10FTHF + ADP <==>  ATP + Formate + THF Reversible 
25 [c] : Ser --> Pyr + NH4 Irreversible 
26 [c] : Thr -->  αKb + NH4 Irreversible 
27 [c] : αKb + CoASH + NAD + HCO3 + ATP --> SucCoA + ADP + NADH + CO2 Irreversible 
28 [c] : Trp --> Ala + (2) CO2 + αKa Irreversible 
29 [c] : Lys + (2) αKG + (3) NADP + FAD --> αKa + (2) Glu + (3) NADPH + FADH2 Irreversible 
30 [c] : αKa + (2) CoASH + (2) NAD --> (2) AcCoA + (2) NADH + (2) CO2 Irreversible 
31 [c] : Val + αKG + CoASH + NAD --> IsobutCoA + Glu + CO2 + NADH Irreversible 
32 [c] : IsobutCoA + FAD + (2) NAD + HCO3 + ATP --> SucCoA + ADP + FADH2 + (2) NADH + CO2 Irreversible 
33 [c] : IsobutCoA --> Isobut Irreversible 
34 [c] : Ile + αKG + (2) CoASH + (2) NAD + FAD + HCO3 + ATP --> AcCoA + SucCoA + ADP + Glu + CO2 + (2) 
NADH + FADH2 
Irreversible 
35 [c] : Leu + αKG + CoASH + NAD --> IsovalCoA + Glu + CO2 + NADH Irreversible 
36 [c] : IsovalCoA + FAD + ATP + CO2 + SucCoA + CoASH --> (3) AcCoA + Succ + FADH2 + ADP Irreversible 
37 [c] : IsovalCoA --> Isoval Irreversible 
38 [c] : Phe + NADH --> Tyr + NAD Irreversible 
39 [c] : Tyr + αKG + SucCoA + CoASH --> Fum + (2) AcCoA + Succ + Glu + CO2 Irreversible 
40 [c] : Met + Ser + ATP --> αKb + NH4 + AMP Irreversible 
41 [c] : Asn <==>  Asp + NH4 Reversible 
42 [c] : Pro + NADP <==>  Glu + NADPH Reversible 
43 [c] : Arg + αKG + NADP --> (2) Glu + NADPH + Urea Irreversible 
44 [c] : His --> Glu + NH4 Irreversible 
45 [c] : Arg -->  Orn +  Urea Irreversible 
46 [c] : Orn -->  PTRSC +  CO2 Irreversible 
47 [c] : Met +  ATP -->  SAM Irreversible 
48 [c] : SAM -->  DSAM +  CO2 Irreversible 
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49 [c] : DSAM +  PTRSC -->  5MTA +  SPRMD Irreversible 
50 [c] : 5MTA + SPRM --> DSAM + SPRMD Irreversible 
 Glycogen Synthesis  
51 [c] : G6P --> G1P Irreversible 
52 [c] : G1P + UMPRN + (2) ATP --> UDPG + (2) ADP Irreversible 
53 [c] : UDPG --> Glycogen + UDP Irreversible 
 Nucleotide Synthesis  
54 [c] : R5P + ATP --> PRPP + AMP Irreversible 
55 [c] : PRPP + (2) Gln + Gly + Asp + (5) ATP + CO2 + (2) N10FTHF --> IMP + (2) Glu + Fum + (5) ADP + (2) THF Irreversible 
56 [c] : IMP + Asp + GTP --> AMPRN + Fum + GDP Irreversible 
57 [c] : IMP + Gln + ATP + NAD --> GMPRN + Glu + AMP + NADH Irreversible 
58 [c] : HCO3 + NH4 + Asp + (2) ATP + NAD --> Orotate + (2) ADP + NADH Irreversible 
59 [c] : Orotate + PRPP --> UMPRN + CO2 Irreversible 
60 [c] : UMPRN + Gln + ATP --> CMPRN + Glu + ADP Irreversible 
61 [c] : AMPRN --> dAMP Irreversible 
62 [c] : GMPRN --> dGMP Irreversible 
63 [c] : CMPRN --> dCMP Irreversible 
64 [c] : UMPRN --> dTMP Irreversible 
 Lipid Synthesis  
65 [c] : Choline + ATP --> Pcholine + ADP Irreversible 
66 [c] : Pcholine + (18) AcCoA + Glyc3P + (22) ATP + (33) NADH --> PC + (16) ADP + (6) AMP + (33) NAD + (18) 
CoASH 
Irreversible 
67 [c] : PC + Ser <==>  PS + Choline Reversible 
68 [c] : PS --> PE + CO2 Irreversible 
69 [c] : Choline + Glyc3P <==>  Glyc3PC Reversible 
70 [c] : G6P --> Inositol Irreversible 
71 [c] : Inositol + (18) AcCoA + Glyc3P + (22) ATP + (33) NADH --> PI + (16) ADP + (6) AMP + (33) NAD + (18) 
CoASH 
Irreversible 
72 [c] : (18) AcCoA + (2) Glyc3P + (22) ATP + (33) NADH --> PG + (16) ADP + (6) AMP + (33) NAD + (18) CoASH Irreversible 
73 [c] : (2) PG --> DPG + Glyc Irreversible 
74 [c] : (16) AcCoA + Ser + Choline + (16) ATP + (29) NADPH --> SM + (2) CO2 + (14) ADP + (2) AMP + (29) 
NADP + (16) CoASH 
Irreversible 
75 [c] : (18) AcCoA + (18) ATP + (14) NADPH --> Cholesterol + (9) CO2 + (18) ADP + (14) NADP + (18) CoASH Irreversible 
 Biomass Formation  
76 For 36.5°C 
[c] : (88.038) Ala + (54.1149) Arg + (54.6624) Asn + (101.835) Asp + (60.4002) Gln + (143.2041) Glu + 
(90.2061) Gly + (15.1986) His + (44.8731) Ile + (91.3887) Leu + (103.7403) Lys + (23.0388) Met + (41.61) 
Phe + (51.8592) Pro + (66.6198) Ser + (54.6843) Thr + (7.01895) Trp + (22.8855) Tyr + (65.3934) Val + 
(9450.507) ATP + (11.043513) AMPRN + (3.055269) Cholesterol + (8.038614) CMPRN + (3.721686) dAMP 
+ (2.665668) dCMP + (2.79444) dGMP + (0.5913) DPG + (3.696063) dTMP + (94.6299) Glycogen  + 
(7.437459) GMPRN + (11.622111) PC + (4.407156) PE + (0.22119) PG + (1.59651) PI + (0.438) PS + 
(1.382985) SM + (11.006064) UMPRN + (0.47085) NAD + (0.02847) NADP + (0.00219) FAD + (0.01095) 
NADH + (0.0876) NADPH + (0.001314) SucCoA + (0.01095) AcCoA + (0.012264) CoASH + (10.95) MTHF + 
(7.665) PTRSC + (1.533) SPRMD + (1.8615) Neu5Ac + (19.1596666087446) GlcNAc + (4.43910147525) 
GalNAc + (14.3965857576054) Mann + (6.32724069101717) Gal + (4.52592703789134) Fuc + (0) Neu5Gc 
--> (1) Biomass + (9450.507) ADP 
For 32°C TS 
[c] : (88.038) Ala + (54.1149) Arg + (54.6624) Asn + (101.835) Asp + (60.4002) Gln + (143.2041) Glu + 
(90.2061) Gly + (15.1986) His + (44.8731) Ile + (91.3887) Leu + (103.7403) Lys + (23.0388) Met + (41.61) 
Phe + (51.8592) Pro + (66.6198) Ser + (54.6843) Thr + (7.01895) Trp + (22.8855) Tyr + (65.3934) Val + 
(9450.507) ATP + (11.043513) AMPRN + (3.055269) Cholesterol + (8.038614) CMPRN + (3.721686) dAMP 
+ (2.665668) dCMP + (2.79444) dGMP + (0.5913) DPG + (3.696063) dTMP + (94.6299) Glycogen  + 
(7.437459) GMPRN + (11.622111) PC + (4.407156) PE + (0.22119) PG + (1.59651) PI + (0.438) PS + 
(1.382985) SM + (11.006064) UMPRN + (0.47085) NAD + (0.02847) NADP + (0.00219) FAD + (0.01095) 
NADH + (0.0876) NADPH + (0.001314) SucCoA + (0.01095) AcCoA + (0.012264) CoASH + (10.95) MTHF + 
(7.665) PTRSC + (1.533) SPRMD + (1.8615) Neu5Ac + (19.1750013522) GlcNAc + (4.43910147525) GalNAc 
+ (14.38125101415) Mann + (5.40043757441596) Gal + (4.48368385448878) Fuc + (0) Neu5Gc --> (1) 
Biomass + (9450.507) ADP 
Irreversible 
 Other by-products  
77 [c] : AcCoA + AMP <==>  Acetate + CoASH + ATP Reversible 
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78 [c] : DHAP + NADH <==>  Glyc3P + NAD Reversible 
79 [c] : Glyc3P <==>  Glyc Reversible 
 Glycosylation  
80 [c] : UDPG <==>  UDPGal Reversible 
81 [c] : Glc + ATP + GTP --> GDPMann + ADP Irreversible 
82 [c] : F6P + Gln + AcCoA + UTP --> UDPNAG + Glu + CoASH Irreversible 
83 [c] : UDPNAG + ATP + 3PG + CTP --> CMPNeu5Ac + UDP + ADP Irreversible 
84 [c] : GDPMann + NADPH --> GDPFuc + NADP Irreversible 
85 [c] : UDPNAG <==>  UDP +  GlcNAc Reversible 
86 [c] : UDPNAG <==>  UDPGalNAc Reversible 
87 [c] : UDPGalNAc <==> GalNAc + UDP Reversible 
88 [c] : GDPMann <==>  Mann + GDP Reversible 
89 [c] : UDPGal <==> Gal + UDP Reversible 
90 [c] : CMPNeu5Ac <==>  CMP +  Neu5Ac Reversible 
91 [c] : GDPFuc <==>  GDP +  Fuc Reversible 
92 [c] : CMPNeu5Ac <==>  CMPNeu5Gc Reversible 
93 [c] : CMPNeu5Gc <==> CMP + Neu5Gc Reversible 
 Vitamin metabolism  
94 [c] : Fol +  NADH -->  THF +  NAD Reversible 
95 [c] : Gly +  THF +  NAD <==>  METTHF +  NH4 +  CO2 +  NADH Reversible 
96 [c] : MTHF +  NADP <==>  METTHF +  NADPH Reversible 
 IgG Formation  
97 [c] : (423.795512610944) Ala + (266.385750784022) Arg + (314.819523653844) Asn + 
(302.711080436388) Asp + (363.253296523666) Gln + (363.253296523666) Glu + (581.205274437866) 
Gly + (133.192875392011) His + (0) Ile + (605.422160872777) Leu + (520.663058350588) Lys + 
(72.6506593047332) Met + (266.385750784022) Phe + (532.771501568043) Pro + (1138.19366244082) 
Ser + (593.313717655321) Thr + (121.084432174555) Trp + (387.470182958577) Tyr + 
(690.181263394965) Val + (10.992)  GDPFuc + (54.962) UDPNAG + (32.977) GDPMann + (21.985) UDPGal 
+ (21.985) CMPNeu5Ac --> (32.977) GDP + (21.985) UDP + (21.985) CMP + (1) IgG 
Irreversible 
 Transport Reactions  
98 Acetate[e] <==> Reversible 
99 ADP[e] <==> Reversible 
100 Ala[e] <==> Reversible 
101 AMP[e] <==> Reversible 
102 Arg[e] <==> Reversible 
103 Asn[e] <==> Reversible 
104 Asp[e] <==> Reversible 
105 ATP[e] <==> Reversible 
106 Biomass[e] <==> Reversible 
107 Choline[e] <==> Reversible 
108 Cit[e] <==> Reversible 
109 CMP[e] <==> Reversible 
110 CO2[e] <==> Reversible 
111 CoASH[e] <==> Reversible 
112 CTP[e] <==> Reversible 
113 FAD[e] <==> Reversible 
114 FADH2[e] <==> Reversible 
115 Fol[e] <==> Reversible 
116 Formate[e] <==> Reversible 
117 Fum[e] <==> Reversible 
118 GDP[e] <==> Reversible 
119 Glc[e] <==> Reversible 
120 Gln[e] <==> Reversible 
121 Glu[e] <==> Reversible 
122 Gly[e] <==> Reversible 
123 Glyc[e] <==> Reversible 
124 Glyc3PC[e] <==> Reversible 
125 GTP[e] <==> Reversible 
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126 His[e] <==> Reversible 
127 IgG[e] <==> Reversible 
128 Ile[e] <==> Reversible 
129 Isobut[e] <==> Reversible 
130 Isoval[e] <==> Reversible 
131 Lac[e] <==> Reversible 
132 Leu[e] <==> Reversible 
133 Lys[e] <==> Reversible 
134 Mal[e] <==> Reversible 
135 Met[e] <==> Reversible 
136 NAD[e] <==> Reversible 
137 NADH[e] <==> Reversible 
138 NADP[e] <==> Reversible 
139 NADPH[e] <==> Reversible 
140 NH4[e] <==> Reversible 
141 Pcholine[e] <==> Reversible 
142 Phe[e] <==> Reversible 
143 Pro[e] <==> Reversible 
144 Pyr[e] <==> Reversible 
145 Ser[e] <==> Reversible 
146 SPRM[e] <==> Reversible 
147 Succ[e] <==>  Reversible 
148 Thr[e] <==> Reversible 
149 Trp[e] <==> Reversible 
150 Tyr[e] <==> Reversible 
151 UDP[e] <==> Reversible 
152 Urea[e] <==> Reversible 
153 UTP[e] <==> Reversible 
154 Val[e] <==> Reversible 
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Supplementary Table 3. FBA estimated flux values in nucleotide synthesis, lipid synthesis 
and protein glycosylation during stationary phase at 36.5°C and 32°C. 
Reaction Equation Subsystem Flux value 
(femtomol/cell/day) 
36.5°C 
(Day7-10) 
32°C  
(Day7-10) 
54 [c] : R5P + ATP --> PRPP + AMP Irreversible Nucleotide  6.26 0.30 
55 [c] : PRPP + (2) Gln + Gly + Asp + (5) ATP + CO2 + (2) 
N10FTHF --> IMP + (2) Glu + Fum + (5) ADP + (2) THF 
Irreversible Nucleotide  1.00 0.00 
56 [c] : IMP + Asp + GTP --> AMPRN + Fum + GDP Irreversible Nucleotide  0.59 0.00 
57 [c] : IMP + Gln + ATP + NAD --> GMPRN + Glu + 
AMP + NADH 
Irreversible Nucleotide  0.41 0.00 
58 [c] : HCO3 + NH4 + Asp + (2) ATP + NAD --> 
Orotate + (2) ADP + NADH 
Irreversible Nucleotide  5.26 0.30 
59 [c] : Orotate + PRPP --> UMPRN + CO2 Irreversible Nucleotide  5.26 0.30 
60 [c] : UMPRN + Gln + ATP --> CMPRN + Glu + ADP Irreversible Nucleotide  0.43 0.00 
61 [c] : AMPRN --> dAMP Irreversible Nucleotide  0.15 0.00 
62 [c] : GMPRN --> dGMP Irreversible Nucleotide  0.11 0.00 
63 [c] : CMPRN --> dCMP Irreversible Nucleotide  0.11 0.00 
64 [c] : UMPRN --> dTMP Irreversible Nucleotide  0.15 0.00 
65 [c] : Choline + ATP --> Pcholine + ADP Irreversible Lipid  2.77 2.63 
66 [c] : Pcholine + (18) AcCoA + Glyc3P + (22) ATP + 
(33) NADH --> PC + (16) ADP + (6) AMP + (33) NAD 
+ (18) CoASH 
Irreversible Lipid  0.66 0.00 
67 [c] : PC + Ser <==>  PS + Choline Reversible Lipid  0.19 0.00 
68 [c] : PS --> PE + CO2 Irreversible Lipid  0.18 0.00 
69 [c] : Choline + Glyc3P <==>  Glyc3PC Reversible Lipid  3.53 3.53 
70 [c] : G6P --> Inositol Irreversible Lipid  0.06 0.00 
71 [c] : Inositol + (18) AcCoA + Glyc3P + (22) ATP + (33) 
NADH --> PI + (16) ADP + (6) AMP + (33) NAD + 
(18) CoASH 
Irreversible Lipid  0.06 0.00 
72 [c] : (18) AcCoA + (2) Glyc3P + (22) ATP + (33) NADH --
> PG + (16) ADP + (6) AMP + (33) NAD + (18) CoASH 
Irreversible Lipid  0.06 0.00 
73 [c] : (2) PG --> DPG + Glyc Irreversible Lipid  0.02 0.00 
74 [c] : (16) AcCoA + Ser + Choline + (16) ATP + (29) 
NADPH --> SM + (2) CO2 + (14) ADP + (2) AMP + 
(29) NADP + (16) CoASH 
Irreversible Lipid  0.06 0.00 
75 [c] : (18) AcCoA + (18) ATP + (14) NADPH --> 
Cholesterol + (9) CO2 + (18) ADP + (14) NADP + (18) 
CoASH 
Irreversible Lipid  0.12 0.00 
79 [c] : UDPG <==>  UDPGal Reversible Glycosylation 0.46 0.30 
80 [c] : Glc + ATP + GTP --> GDPMann + ADP Irreversible Glycosylation 1.17 0.61 
81 [c] : F6P + Gln + AcCoA + UTP --> UDPNAG + Glu + CoASH Irreversible Glycosylation 1.53 0.76 
82 [c] : UDPNAG + ATP + 3PG + CTP --> 
CMPNeu5Ac + UDP + ADP 
Irreversible Glycosylation 0.07 0.00 
83 [c] : GDPMann + NADPH --> GDPFuc + NADP Irreversible Glycosylation 0.28 0.15 
84 [c] : UDPNAG <==>  UDP +  GlcNAc Reversible Glycosylation 0.78 0.00 
85 [c] : UDPNAG <==>  UDPGalNAc Reversible Glycosylation 0.18 0.00 
86 [c] : UDPGalNAc <==> GalNAc + UDP Reversible Glycosylation 0.18 0.00 
87 [c] : GDPMann <==>  Mann + GDP Reversible Glycosylation 0.58 0.00 
88 [c] : UDPGal <==> Gal + UDP Reversible Glycosylation 0.25 0.00 
89 [c] : CMPNeu5Ac <==>  CMP +  Neu5Ac Reversible Glycosylation 0.07 0.00 
90 [c] : GDPFuc <==>  GDP +  Fuc Reversible Glycosylation 0.18 0.00 
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